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Microvascular dysfunction in 
ankylosing spondylitis is associated 
with disease activity and is 
improved by anti-TNF treatment
Bogdan Batko1, Pawel Maga2, Karol Urbanski  3, Natalia Ryszawa-Mrozek3, Agata Schramm-
Luc3, Mateusz Koziej  4, Tomasz Mikolajczyk5, Eilidh McGinnigle5, Marta Czesnikiewicz-
Guzik3,6, Piotr Ceranowicz7 & Tomasz J. Guzik3,5
Ankylosing spondylitis (AS) is associated with high cardiovascular morbidity and mortality. 
Recent studies indicate that microvascular dysfunction may underlie cardiovascular risk in AS. 
We hypothesized, that microvascular morphology and dysfunction is linked to AS activity and is 
modifiable by TNF-α inhibitor (TNFi) treatment. Functional Laser Doppler Flowmetry with post-
occlusive reactive hyperemia, and structural nailfold capillaroscopy were performed in 54 patients 
with AS and 28 matched controls. Active AS was diagnosed based on BASDAI ≥ 4 (n = 37). Effects of 
3-month TNFi on microcirculation in active AS were studied. AS was associated with prolonged time 
to peak hyperemia compared to healthy controls. High disease activity was associated with increased 
time to peak hyperemia and decreased peak hyperemia when compared to patients with inactive 
AS. In capillaroscopy, AS was associated with morphological abnormalities indicating increased 
neoangiogenesis and pericapillary edema compared to controls. Microvascular function improved 
following 3 months of TNFi in reference to basal flow as well as post-occlusive parameters. TNFi 
reduced pericapillary edema, while other parameters of capillary morphology remained unchanged. 
Microvascular dysfunction and capillary neovascular formation are associated with disease activity of 
AS. Anti-TNF-α treatment may restore microcirculation function and capillary edema but does not 
modify microvascular structural parameters.
Ankylosing spondylitis (AS) is associated with elevated cardiovascular (CV) risk and increased mortality1–4, as an 
independent CVD risk factor. Registry data suggest a 30–50% increased risk of CV events compared to general 
population5. The mechanisms of this link are not thoroughly investigated but are thought to be related to dysreg-
ulated CV risk factors profile as well as directly to inflammatory mechanisms of AS. Endothelial dysfunction is a 
key mechanism of increased CVD risk6 with conventional causes such as hypertension, diabetes mellitus (DM), 
smoking and hypercholesterolemia7–9, but can also be induced by inflammation10. While the majority of studies 
have focused on the dysfunction of large conduit vessels in AS11,12, less is known in relation to microvascular dys-
function in this disease. While vascular dysfunction in conduit vessels underlies atherosclerosis, microvascular 
dysfunction serves as a key mechanism for hypertension, cognitive dysfunction and heart failure via effects in 
vasa vasorum contributing to perivascular inflammation – an early feature of vascular disease13–15. Therefore, 
characterization of microcirculation in AS and its links to AS disease activity, is of primary importance. Skin 
microvasculature offers a perfect model to study arteriole function and capillary morphology16. So far only one, 
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recent study has shown that NO-mediated, acetylcholine induced vasorelaxation in microvessells is impaired in 
AS and may improve with therapy17. We hypothesized that microvascular morphology and function in patients 
with AS is linked to disease activity and is modifiable by TNF-α inhibitor (TNFi) treatment, reducing disease 
activity. Presence of microvascular dysfunction has been recently identified in a smaller and mixed populations 
of patients with inflammatory joint diseases17,18. It, however, remains unclear whether this relationship is caused 
by prevalence of classical CVD risk factors or is linked to AS specific inflammatory factors. It is unclear how such 
dysfunction is linked to AS disease activity. Finally, microvascular morphological changes have not been assessed 
so far in this context. Therefore, using physiological stimulus – hyperemia and Laser Doppler Flowmetry (LDF), 
in a well powered analysis, we have confirmed presence of microvascular dysfunction in a low classical CVD 
risk population, and observed a clear relationship between functional microvascular impairment, morpholog-
ical changes and AS activity. Moreover, we demonstrated that functional impairment and capillary edema can 
be reversed by anti-TNF treatment, suggesting a key role of this drug therapy in microvascular dysfunction in 
patients with highly active AS. Thus, simple tools for the measurement of microvascular function in the skin, 
available in typical outpatient setting, may give a valuable insight into microvascular function and structure and 
can be monitored in relation to its effects on cardiovascular risk.
Results
Microvascular function and morphology in Ankylosing Spondylitis. Microcirculation parameters 
studied using Laser Doppler Flowmetry (LDF) with Post-Occlusive Reactive Hyperemia (PORH) were impaired 
in AS patients compared to healthy controls. The groups were relatively young [40.0 (34–48) and 43.5 (39–48) 
years old respectively], matched for major clinical factors affecting microvascular function and their occurrence 
was low when compared to general population (hypertension <15%) or absent (diabetes mellitus, thyroid dys-
function, Raynaud’s phenomenon, and previous cardiovascular events) (Table 1). Time to peak hyperemia was 
almost two-fold longer in comparison to healthy controls [9.4 s (6.8–12.5) vs 5.2 s (3.8–6.1); p < 0,001] (Table 2). 
In capillaroscopy, AS was associated with an abnormal microvascular morphology, with increased occurrence 
of loops enlargements, bushy and coiled, and branched capillaries as well as pericapillary edema compared to 
healthy controls (20.4% vs 3.6%, p = 0.04; 75.9% vs. 21.4%, p < 0.001; 37% vs. 14.3%, p = 0.03; 46.3% vs. 3.6%, 
p < 0.001 respectively) (Table 3).
Microvasculature, nailfold capillaroscopy and disease activity. To evaluate whether the observed 
differences are associated with disease activity we divided patients into 2 groups based on Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI). No differences in age, sex, body mass index (BMI), smoking status 
nor disease duration were observed between the groups (Table 1). Patients with active disease (BASDAI ≥ 4) had 
impaired microcirculation function in PORH compared to the inactive group (BASDAI < 4). They were charac-
terized by decreased peak hyperemia [79.1PU (36.0–131.9) vs 183.1PU (95.5–281.7); p = 0.02] and increased time 
to peak [10.1 s (7.7–14.2) vs 7.1 s (5.2–11.0); p = 0.01). Basal flow was not influenced by disease activity [31.1PU 
(18.3–53.5) vs. 38.2PU (23.1–96.5); p = 0.11], (Fig. 1). No changes were observed in capillaroscopy between 
patients with active and inactive disease (p > 0.05) (see Supplementary Table S1).
TNF-α inhibitor therapy and disease activity. TNF-α inhibitor treatment effectively reduced AS dis-
ease activity. The values of BASDAI, Visual Analog Scale (VAS) pain, Ankylosing Spondylitis Disease Activity 
score (ASDAS-CRP), and ASDAS-ESR were significantly lowered after the first 3 months of therapy [6.70 
All AS (n = 54) Inactive (n = 17) Active (n = 37)




P value AS vs 
Healthy controls
Age, years 40.0 (34–48) 41.0 (35–47) 40.0 (31–48) 0.79 43.5 (39–48) 0.24
Male, % 66.7 76.5 62.2 0.30 46.4 0.08
Body Mass Index 26.7 (22.3–29.3) 27.1 (22.8–30.0) 26.4 (22.0–28.9) 0.51 26.4 (24.4–28.9) 0.62
Smoking, % 20.4 17.7 21.6 1 17.9 0.79
Hypercholesterolemia,% 68.5 82.4 62.1 0.21 85.7 0.09
Hypertension, % 13.0 11.8 13.5 1 0 0.09
Disease duration, years 6.5 (2.0–12.5) 7.0 (3.0–12.0) 6.0 (2.0–13.0) 0.54 — —
BASDAI 6.2 (3.8–7.2) 2.0 (1.6–3.2) 6.7 (6.0–7.7) <0.001 — —
VAS pain 64.0 (35.0–74.0) 23.0 (8.0–35.0) 70.0 (62.0–78.0) <0.001 — —
ASDAS – CRP 3.5 (2.0–4.2) 1.4 (1.0–1.9) 3.8 (3.4–4.3) <0.001 — —
ASDAS - ESR 3.3 (1.9–3.6) 1.4 (0.8–1.9) 3.4 (3.2–4.0) <0.001 — —
CRP, mg/dl 8.0 (3.2–14) 3.3 (1.8–4.3) 9.7 (6.1–20.6) <0.001 1.4 (0.8–2.5) <0.001
ESR, mm/h 12.1 (6.1–22.3) 6.1 (3.0–10.3) 17.4 (9.0–26.6) 0.002 — —
Table 1. Baseline characteristics of Ankylosing Spondylitis patients with active and inactive disease and healthy 
controls. Data are median (IQR). Mann-Whitney U test was used for comparing continuous variables. Chi-
square test or Fisher exact test were used for dichotomous variables. AS – Ankylosing Spondylitis.
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(6.0–8.0) to 3.20 (2.5–3.7), p < 0.001; 72.0 (65.0–78.0) to 23.0 (11.0–35.0), p < 0.001; 4.0 (3.5–4.3) to 1.8 (1.5–2.0), 
p < 0.001; 3.4 (3.3–3.9) to 1.4 (1.3–2.0), p < 0.001, respectively].
TNF-α inhibitor therapy and microcirculation parameters. To evaluate the influence of treatment 
with TNF-α inhibitors on microcirculation function, we performed LDF before commencing and after 3 months 
of TNFi therapy. There was an improvement in all observed microcirculation parameters. Basal flow and peak 
hyperemia were significantly increased [28.3PU (12.1–45.4) vs. 68.2PU (44.4–91.2); p = 0.001 and 73.6PU (32.0–
128.1) vs. 201.1PU (115.1–220.1); p < 0.001, respectively]. Meanwhile, time to peak was decreased in comparison 
Ankylosing Spondylitis (n = 54) Healthy Controls (n = 28) P value
Basal Flow [PU] 32.1 (18.9–63.1) 29.0 (24.6–35.5) 0.41
Peak hyperemia [PU] 98.2 (38.3–184.5) 96.7 (79.5–117.7) 0.75
Time to peak [s] 9.4 (6.8–12.5) 5.2 (3.8–6.1) <0.001
Table 2. Microvascular function parameters in patients with Ankylosing Spondylitis and healthy controls. Data 
are median (interquartile range). Mann-Whitney U test was used.
Ankylosing 
Spondylitis (n = 54)
Healthy Controls 
(n = 28) P value
Capillary disorganization 25.9% 21.4% 0.65
Loss of capillaries 22.2% 35.7% 0.19
Loop enlargements 20.4% 3.6% 0.04
Megacapillaries 0% 0% —
Bushy and coiled capillaries 75.9% 21.4% <0.001
Branched capillaries 37.0% 14.3% 0.03
Pericapillary edema 46.3% 3.6% <0.001
Table 3. Capillaroscopic parameters in patients with Ankylosing Spondylitis and healthy controls. The number 
and morphology were evaluated in Ankylosing Spondylitis patients and healthy controls. The percentages 
reflect the number of participants in which the mentioned structures were present. Chi-square test was used.
Figure 1. Disease activity and microvascular function. Basal flow (a), peak hyperemia (b) and time to peak 
hyperemia (c) were measured in patients with active (n = 37) and inactive (n = 17) disease based on BASDAI 
score. Mann-Whitney U test was used. Data are expressed as median, interquartile range (box), 10–90 
percentile (whiskers).
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to values obtained before biological treatment [10.7 s (8.3–14.6) vs. 4.8 s (3.7–6.1); p < 0.001]; (Fig. 2a–c). Example 
of the results of LDF with hyperemia test before and after biologic treatment is shown in Fig. 2d.
TNF-α inhibitor therapy and nailfold capillaroscopy. TNF-α inhibitor treatment influenced only one 
capillaroscopy parameter. At 3 months of TNFi therapy, reduced pericapillary edema was noted (36.4% vs 4.5%; 
p = 0.02); (Table 4 and Supplementary Fig. S1). There was no change in other morphological parameters, such as 
the type of visible capillaries, capillary density and distribution.
Discussion
We compared microvascular morphology and function in well matched cohorts of AS patients with differing 
levels of severity and healthy controls. Subjects matched for age, sex, BMI and major CVD risk factors (low tradi-
tional risk population). Our study demonstrates, that microvascular impairment in AS is associated with disease 
activity. Anti-TNF-α treatment restores microvascular function and diminishes peri-capillary edema assessed 
by capillaroscopy in patients with high disease activity. While impaired microvascular function has been shown 
recently by smaller studies using invasive methods17 or in mixed un-defined arthritis populations18, we have used 
appropriately powered population size of subjects with AS with low traditional CV risk. We also demonstrated 
that simple, non-invasive techniques, available in most rheumatology clinics may be useful in assessing micro-
vascular status. Finally, we have shown that TNFi effects persist past the therapy initiation17, and are very clear at 
3 month timepoint.
Several chronic inflammatory diseases are associated with increased cardiovascular risk19. Most previous stud-
ies have focused on rheumatoid arthritis (RA)20 and systemic lupus erythematosus (SLE)21,22. The data regarding 
spondyloarthropaties, including AS are limited, although CV mortality and morbidity increase is evident23. It is 
not clear however, if increased CV risk is caused by inflammatory disease activity or is secondary to traditional 
risk factors, such as dyslipidemia24 or hypertension6, that are often present in AS.
Numerous model and observational studies and more recently clinical randomized trials, such as CANTOS, 
indicate an important role of inflammation in mediating increased cardiovascular risk25–27. Inflammatory cells 
and mediators induce endothelial dysfunction6, subsequent plaque formation and plaque instability resulting in 
acute coronary syndromes. Thus, anti-inflammatory therapies may provide several protective mechanisms in vas-
cular dysfunction in atherosclerosis28. A recent meta-analysis suggests that TNF-α inhibitors improve endothe-
lial function in patients with Rheumatoid Arthritis29. Comparable effects in AS may be attributed to reducing 
systemic inflammation present in these two diseases. On the other hand, inflammation is less pronounced in 
spondyloarthropaties, so the effects may be weaker and more difficult to confirm. Studies of inflammatory mech-
anisms of cardiovascular risk focus on macrovascular dysfunction and disease. While this is important for acute 
Figure 2. TNF-α inhibitor treatment and microvascular function. Basal flow (a), peak hyperemia (b) and time 
to peak hyperemia (c) were measured in patients before and 3 months after TNFi treatment (n = 22). (d) Sample 
test result of LDF and PORH: (left) patient before TNFi treatment, (right) after TNFi treatment: A - basal 
flow, B - PORH test – peak hyperemia after 5-minute occlusion. Wilcoxon signed-rank test was used. Data are 
expressed as median, interquartile range (box), 10–90 percentile (whiskers). TNFi – TNF-α inhibitor, LDF – 
Laser Doppler Flowmetry, PORH – Post-occlusive Reactive Hyperemia.
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MI development or ischemic strokes, numerous chronic conditions are associated with microvascular dysfunc-
tion, which may be a key mechanism for heart failure development, cognitive impairment and vascular demen-
tia30,31. Moreover, it has been reported that microvascular dysfunction may lead to CV events even in the absence 
of obstructive epicardial coronary artery disease32. Therefore, identification of profoundly impaired microvascu-
lar flow mediated endothelial function and abnormalities within microvessel morphology may have numerous 
long term clinical consequences. Thanks to careful selection of study population without CAD or diabetes with 
low prevalence of other classical risk factors and matching for age, sex and BMI, we were able to assess effects 
particularly attributable to AS itself. This was further supported by links to disease activity and improvement with 
TNFi therapy. While the fact that we studied patients treated using different TNF-α inhibitors could be consid-
ered as limitation, it also suggests, that the observed effects are not limited to one biologic agent. The question 
remains whether the type of TNF-α inhibitor is of importance and affects the quantity and kind of changes in the 
microcirculation. This could be essential in the treatment choice for patients with high CVD risk and such large 
randomized studies will hopefully clarify this in the future.
We used much simpler methodology of assessment than used in a seminal study of van Eijk et al.17 Approach 
presented in this study is non-invasive, reproducible and poses little discomfort to the patient33. Thus, it is poten-
tially valuable for vascular risk assessment in AS patients, accessible in the rheumatology clinics. The measure-
ments consisted of assessment of basal flow and dynamic PORH tests, which reflect ability of the vasculature 
to respond to external factors. Dynamic variables such as peak hyperemia and time to peak are more sensitive 
in establishing endothelial dysfunction. Indeed, the observed relationships were visible particularly in PORH. 
Basal flow was increased only in reference to TNFi treatment which may be attributed to a greater potency of this 
factor than disease activity itself. Reversibility of these microvascular changes with clinically effective therapies 
show that such improvement is aligned with the fact that low disease activity or TNFi therapy reduce inherent 
CVD risk34 and atherosclerosis progression in AS35,36. Although LDF and PORH are considered valuable tools 
to study microcirculation function16,33, they have some disadvantages such as indirect blood flow measurement 
and lack of standardization. Skin vascular bed is also very sensitive to environmental factors which may affect 
the results and decrease reproducibility. Most important are skin and room temperature and patient’s stress16. To 
overcome this, we controlled environmental temperature before measurements and measured skin temperature 
before examination which showed no differences between groups (see Supplementary Table S2). Additionally, 
Bland-Altman plots showed good reproducibility of the performed measurements (see Supplementary Fig. S2). 
An unexplained issue remains the mechanism of endothelial function improvement after TNFi treatment. LDF 
assessments were performed at baseline and after 3 months of treatment. Such design made it impossible for us to 
distinguish whether these effects were chronic or acute. However, the improvement in endothelial function after 
TNFi treatment is more pronounced and affects post-occlusive as well as basal flow indices, compared to active/
inactive disease analysis. Based on that we can speculate that the effect of TNFi can be attributed not only to sta-
bilization of the disease activity and inflammation but also to some other mechanisms – probably neutralization 
of the direct effects of circulating TNFα.
Nailfold capillaroscopy is also widely used in rheumatology, mainly in diagnosing and monitoring Systemic 
Sclerosis (SSc). It describes the morphological state of microvasculature, and may be affected by ongoing inflam-
mation. SSc capillary pattern may be sometimes observed in other connective tissue disorders such as polymyosi-
tis/dermatomyositis, SLE, undifferentiated connective tissue disease37 and Sjögren’s syndrome38. We characterized 
substantial changes in nailfold capillaroscopy between AS patients and healthy controls. Increased occurrence of 
capillary ramifications and distinct heterogenous shape are hallmarks of ongoing neoangiogenesis. The presence 
of pericapillary edema may indicate local plasma extravasation or synthesis of extracellular matrix. Microvascular 
abnormalities in AS are not only limited to functional changes but also affect the morphology, similar to other 
connective tissue diseases. Neoangiogenesis was not accompanied by other alterations such as capillary loss as in 
late SSc pattern. Thus, structural changes seem to be secondary to functional impairment which lead to abnormal 
blood flow, hypoxia and angiogenesis. Interestingly, such morphological abnormalities were already observed in 
subjects with low disease activity. 3 months of TNFi treatment, in the active disease group, led to a decrease in 
pericapillary edema, while other parameters were unchanged indicating that while functional changes and edema 
are reversible, morphological remodeling and number of capillaries is not. While there is no direct evidence of 





Capillary disorganization 27.3% 31.8% 1
Loss of capillaries 27.3% 13.6% 0.25
Loop enlargements 13.6% 18.2% 1
Megacapillaries 0% 0% —
Bushy and coiled capillaries 86.4% 77.3% 0.62
Branched capillaries 31.8% 31.8% 1
Pericapillary edema 36.4% 4.5% 0.02
Table 4. Capillaroscopic parameters before and after TNF-α inhibitor treatment. The number and morphology 
were evaluated before and 3 months after TNFi treatment (n = 22). The percents reflect the number of participants 
in which the mentioned structures were present. McNemar’s test was used. TNFi – TNF-α inhibitor.
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edema, that is clearly modified by anti-TNFα treatment, likely reflects systemic inflammation, which may provide 
a particularly valuable clinical clue.
The limitation of the study are relatively small study groups. However, these were sufficient for achieving 
sufficient statistical power and were comparable to numerous previous publications17,36,39. As treatment was per-
formed according to clinical indication rather than in randomized double blinded fashion, the results should be 
verified using RCT. Vascular study investigators, were however blinded to the study groups in the initial part of 
the study, were not part of rheumatology treatment team and did not have access to data regarding treatment of 
the patients.
In conclusion, this work demonstrates that Ankylosing Spondylitis is associated with changes in microvascu-
lar function and morphology, which may explain the increased cardiovascular risk seen in this chronic condition. 
Microvascular changes were more pronounced in patients with high disease activity and treatment with TNF-α 
inhibitors significantly improved blood flow in microcirculation and reduced pericapillary edema. This suggests 
that TNF-α inhibitors may be effective not only in improving the signs and symptoms of AS but also in prevent-
ing cardiovascular complications, warranting future randomized outcome trials.
Patients and Methods
Subject characteristics and study design. 54 AS patients, fulfilling modified New York diagnostic cri-
teria40, were recruited consecutively. 28 healthy controls were matched for age, sex, and BMI with no chronic or 
acute conditions, nor regular medication use (including oral contraceptives). Patients and controls were tested in 
the same settings in terms of days booked. Matching the population control showed a similar distribution of tra-
ditional CV risk factors (Table 1). Power calculation indicated at least 23 patients per group should be studied to 
observe 30% difference in time to peak hyperemia with 90% power, p < 0.05 (two-sided). Using Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI), AS patients were assigned to active AS group (n = 37; BASDAI ≥ 4) 
or inactive AS (n = 17; BASDAI < 4). Both AS groups were treated with non-steroidal anti-inflammatory drugs 
(NSAIDs) and had no history of corticosteroid or biological anti-inflammatory therapy.
22 patients with high disease activity who had no observed BASDAI improvement over 3 months, despite 
use of 2 consecutive NSAIDs, were included in a sub-study, and were treated with TNF-α inhibitor compounds 
(TNFi) for 3 months. 13 (59%) received adalimumab (40 mg/2 weeks s.c.); 6 (27%) etanercept (50 mg/week s.c.) 
and 3 (14%) infliximab (5 mg/kg i.v. 0, 2, 6, then 8 weekly). Exclusion criteria were in accordance with the con-
traindications advised by Assessment of SpondyloArthritis international Society (ASAS)41. There were no modi-
fications in concomitant medications throughout the 3 months of TNFi therapy. The study protocol was approved 
by the Local Ethics Committee of Medical Board of Krakow, Poland (Decision No. 10/KBL/OIL/2013), with all 
study subjects providing written informed consent. The research was carried out in compliance with the Helsinki 
Declaration.
Capillaroscopy. Capillaroscopy evaluated microvessells of the nailfold using a stereo-microscope (Stemi 
2000 C, Carl Zeiss, Germany). Capillary visualization was performed using a cold source of light (KL 1500 elec-
tronic, Carl Zeiss, Germany), with the use of immersive oil and 100× magnification. The procedure and patient 
preparation was performed according to previous recommendations42. Each test was carried out in a temperature 
controlled standardized and maintained at 20–22 °C. Study participants followed the specific diet and lifestyle 
used for our previous flow mediated dilatation studies43. Testing was preceded by a 15-minute rest in standardized 
conditions. Each capillaroscopy assessment was undertaken by two expert investigators who were blinded to the 
participants’ study group and who were not members of therapeutic team. After the examination final result was 
obtained based on a consensus meeting. The nailfolds of four fingers on both hands were analyzed (without a 
thumb). The changes must have been present in at least one finger to be relevant but in the majority of cases were 
observed in two or more fingers. Morphological parameters were analyzed according to previous observations44 
with some modifications and defined as follows. Capillary disorganization - irregular capillary distribution and 
orientation with shape heterogeneity of the loops. Loss of capillaries – less than 5 capillaries in a field of view. 
Loop enlargements in the efferent, apical, and afferent and efferent part (sometimes called Raynaud loops)- an 
increase in capillary diameter (homogeneous or irregular) >20 µm. Megacapillaries - enlarged loops with a diam-
eter >50 µm. Capillary ramifications: branching, bushy or coiled capillaries - heterogenous in shape capillaries 
with visible branches. Capillaries with distinct heterogeneous shape are one of the main morphological features 
of angiogenesis. Pericapillary edema – foggy or light aspect around capillaries.
Laser Doppler Flowmetry (LDF). The microcirculation function was assessed using Laser Doppler 
Flowmetry (LDF) using the Periflux4001 Master apparatus (Perimed AB, Jarfalla, Sweden). The assessment was 
based on a study of basal flow and Post-Occlusive Reactive Hyperemia (PORH) test using laser (helium-neon; 
780 nm) measuring depth of 0.5–1.0 mm with a probe of standard fiber separation (0.25 mm). Flow parame-
ters obtained allow for sensitive quantification of perfusion and spectrum analysis of blood flow in real time16. 
The probe was stabilized on the dorsal side of distal phalanx of the middle finger. Adhesion of the probe to the 
skin was controlled by the flowmeter sensor. Each test was carried out in a temperature controlled standard-
ized. Study participants followed the specific diet and lifestyle used for our previous flow mediated dilatation 
studies43. Testing was preceded by a 15-minute rest in standardized conditions. Finger skin temperature was 
measured using ELLAB CTD-85 system (Copenhagen, Denmark) using the ELLA PRC A probe. The probe was 
positioned on lateral aspect of the distal phalanx and was stabilized using the pressure cuff of the occlusion test 
(see Supplementary Fig. S3). Skin temperature measurements are essential to ensure standardization of the assay, 
and, as expected no differences in skin temperature were observed between studied groups (see Supplementary 
Table S2).
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Following 5 minute basal flow registration, PORH test was performed on the second, third and fourth fin-
ger of the hand and average was reported as previously described45. Briefly, arterial occlusion was achieved for 
5 minutes by inflation of a blood pressure cuff over the proximal phalanx of the finger to supra-systolic pressure 
values to measure the biological zero. Thereafter, the cuff was deflated and the PORH maximal blood inflow and 
the time to peak hyperemia were measured. LDF measurements are expressed in arbitrary perfusion units (PU). 
Microvascular assessment was undertaken by the same expert in microcirculation evaluation who was blinded to 
the participants study group and who was not a member of therapeutic team. The intra-observer variability was 
systematically evaluated by serial repeated measurements within a range of possible outputs in a stable disease 
state. No measurements were rejected for technical reasons. Intra-class correlation coefficients for LDF measure-
ments were: 0.96 (0.90–0.98 CI) for basal flow, 0.93 (0.83–0.97 CI) for peak hyperemia and 0.97 (0.91–0.98 CI) 
for time to peak. There was no systematic difference between the first and second measurement. Bland-Altman 
graph for repeatability is shown on Supplementary Fig. S2. The interobserver reliability was calculated based on 
preliminary experiments using the reliability statistics of the interclass correlation (ICC 1, 2). The ICC coefficients 
were: 0.946 (0.913–0.987CI) for basal flow, 0.979 (0.948–0.993 CI) for peak hyperemia and 0.975 (0.951–0.991CI) 
for time to peak.
Statistical analysis. The statistical analyses were conducted with STATISTICA v12 (StatSoft Inc., Tulsa, OK, 
USA) for Microsoft Windows v10. Values of measurable parameters were presented as medians with quantiles 
(Q1–Q3). Box-and-Whisker plots were generated for microcirculation parameters. Statistical comparisons for 
categorical data were performed using the chi-square or Fisher exact tests and McNemar test on paired nominal 
data. To compare the statistical significance for continuous data of differences between measurable parameters 
Mann-Whitney U test and the Wilcoxon rank-sign test were used. The significance level of p < 0.05 was used to 
test the null hypothesis.
The datasets generated in this study are available from the corresponding author on reasonable request.
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